Wuxi Biologics (Cayman) Inc. is a major player in the biotechnology and medical research sector, specializing in providing comprehensive solutions for the discovery, development, and manufacturing of biologic drugs. As an investment holding company, it operates through two main business segments. The Biologics segment focuses on end-to-end services that encompass biologics discovery, process development, and large-scale manufacturing. Its WuXi XDC segment delivers contract research, development, and manufacturing organization (CRDMO) services, particularly for antibody-drug conjugates (ADCs) and various bioconjugates, catering to both domestic and international clientele. Headquartered in Wuxi, China, and supported by a workforce of over 12,000 employees, the company plays a critical role in advancing biologics innovation and accelerating drug development for pharmaceutical and biotechnology companies worldwide. Wuxi Biologics (Cayman) Inc.'s business model helps lower the barriers for biopharma firms to bring new therapeutic products to market by offering state-of-the-art technical expertise and integrated solutions throughout the biologics lifecycle.